Xarelto Litigation May Follow Praxada’s Footsteps 

As litigation against Xarelto’s manufacturers Bayer AG and Janssen Pharmaceuticals begins to heat up, plaintiffs can’t help but compare it to the 2014 litigation of “cousin” blood-thinner Pradaxa. Over 300 Xarelto suits have been consolidated into a multi-district litigation (MDL) alleging that the drug was unlawfully marketed as a superior, safer, and more effective alternative to generic competitor anticoagulant warfarin, though the drug carries a dangerous bleeding risk. Drugmakers’ failure to warn patients of the lack of a bleeding antidote for Xarelto is at the crux of the litigation surrounding the drug, which has led to fatal patient bleed-outs. Pradaxa’s manufacturer Boehringer Ingelheim has faced thousands of lawsuits related to the same deadly bleeding issue, leading to $650 million in settlements in state and federal courts for 4,000 claims in May 2014.

Real Time Analytics